Drug intelligence / Profile preview

diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine

Development stage
Approved
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This vaccine is a combination immunization product containing **diphtheria toxoid**, **tetanus toxoid**, **acellular pertussis antigens**, and **inactivated poliovirus**. It is designed to induce active immunity against diphtheria, tetanus (lockjaw), pertussis (whooping cough), and poliomyelitis. All components are inactivated; the vaccine does not contain live organisms. Upon intramuscular administration, the vaccine stimulates the immune system to produce antibodies and cellular immune responses to the four agents, thereby protecting against infection and disease. This vaccine is primarily used for booster immunization in children aged 4–6 years and sometimes older children/adolescents as per local recommendations. It is not used for primary immunization in infants, for whom hexavalent or pentavalent combinations are typically used.

Brand names
KinrixQuadracelAdacel-PolioBoostrix-Polio
Other names
DTaP-IPVTdap-IPV

Beyond the preview

Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis + inactivated poliovirus vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call